Blackstone Is Said to Consider Selling Alinamin Pharmaceutical

Blackstone Inc. is considering a sale of Japanese consumer health-care firm Alinamin Pharmaceutical Co., which used to be owned by Takeda Pharmaceutical Co., according to people familiar with the situation.

Blackstone, the world’s biggest alternative asset manager, is working with financial advisers on a potential sale of Tokyo-based Alinamin, which could be valued at about ¥300 billion ($1.9 billion), the people said.

Alinamin is attracting interest from funds including CVC Capital Partners Plc, EQT ABand Seoul-based MBK Partners, the people said, asking not to be identified discussing a private matter.

Other potential options include an ...